Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc. today announced that Dr. Shaker Mousa, Professor of Pharmacology and Executive Vice President and Chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy, will present new preclinical data detailing the observed antithrombotic effect of Othera’s lead compound, OT-551, and related Othera compounds. This work stems from previous ocular studies on OT-551 eye drops, as well as studies on novel, orally-available analog compounds under development for non-ophthalmic indications. Dr. Mousa’s talk will be presented at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress in Geneva, Switzerland on July 9, 2007. The ISTH holds its congress every other year and the organization includes 2,800 thrombosis, hemostasis and vascular biology researchers and clinicians from more than 70 countries.

MORE ON THIS TOPIC